Jupiter Neurosciences (NASDAQ: JUNS) has announced the launch of Nugevia™ PWR, a mitochondrial health supplement designed to enhance cellular energy, endurance, and recovery. The product leverages the company's proprietary JOTROL™ resveratrol-based platform technology and will be commercially available in Fall 2025.
The supplement combines JOTROL™, which showed a nine-fold increase in resveratrol bioavailability in Phase I trials, with NovaSOL® solubilized CoQ10. The product targets the longevity and wellness markets, projected to reach $8 trillion by 2030. PWR is designed as a two-capsule daily regimen and will join GLO in Jupiter's Nugevia™ product line.
The company positions PWR as a strategic revenue opportunity, aiming to generate high-margin returns to support its therapeutic development programs while addressing growing consumer demand for scientifically validated supplements.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.